Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-finding study of Org 25969 (sugammadex) for reversal of rocuronium or vecuronium in Caucasian surgical patients
2005-001134-32Phase 2Completed
- Sponsor
- Organon & Co.
- Start
- Aug 2005
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Sugammadex (5 arms), sponsored by Organon & Co. Primary endpoint: Time to recovery of T4/T1 ratio to 0.9. Started Aug 2005; status: completed.
02
Drugs
Sugammadex
Beyond the preview
Go deeper on 2005-001134-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001134-32.